lobbying_filings_raw: d6e183a0-8eff-44fc-992d-19e6a80c40c4
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence | income_amount | expense_amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| d6e183a0-8eff-44fc-992d-19e6a80c40c4 | Q4 | 400339576 | PRIME THERAPEUTICS | 189439 | PRIME THERAPEUTICS | 2009 | fourth_quarter | 2010-01-18T12:00:55.087000-05:00 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/d6e183a0-8eff-44fc-992d-19e6a80c40c4/", "filing_uuid": "d6e183a0-8eff-44fc-992d-19e6a80c40c4", "filing_type": "Q4", "filing_type_display": "4th Quarter - Report", "filing_year": 2009, "filing_period": "fourth_quarter", "filing_period_display": "4th Quarter (Oct 1 - Dec 31)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/d6e183a0-8eff-44fc-992d-19e6a80c40c4/print/", "filing_document_content_type": "text/html", "income": null, "expenses": "18000.00", "expenses_method": "a", "expenses_method_display": "Method A - Reporting amounts using LDA definitions only", "posted_by_name": "Jerome L. Steffl, Vice President", "dt_posted": "2010-01-18T12:00:55.087000-05:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "1305 Corporate Center Drive", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "Eagan", "registrant_state": "MN", "registrant_zip": "55121", "registrant": {"id": 400339576, "url": "https://lda.senate.gov/api/v1/registrants/400339576/", "house_registrant_id": null, "name": "PRIME THERAPEUTICS", "description": "Pharmacy Benefit Management", "address_1": "2900 Ames Crossing Road", "address_2": null, "address_3": null, "address_4": null, "city": "Eagan", "state": "MN", "state_display": "Minnesota", "zip": "55121", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "DAVID ROOT", "contact_telephone": "+1 804-834-2626", "dt_updated": "2026-01-28T13:11:38.733325-05:00"}, "client": {"id": 189439, "url": "https://lda.senate.gov/api/v1/clients/189439/", "client_id": 12, "name": "PRIME THERAPEUTICS", "general_description": null, "client_government_entity": false, "client_self_select": true, "state": "MN", "state_display": "Minnesota", "country": "US", "country_display": "United States of America", "ppb_state": "MN", "ppb_state_display": "Minnesota", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2010-06-16"}, "lobbying_activities": [{"general_issue_code": "LBR", "general_issue_code_display": "Labor Issues/Antitrust/Workplace", "description": "H.R. 1204 Community Pharmacy Fairness Act", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 48245, "prefix": "mr", "prefix_display": "MR.", "first_name": "JERRY", "nickname": null, "middle_name": null, "last_name": "STEFFL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "S. 1697 Affordable Health Choices Act\nS. 1796 America's Health Choices Act\nH.R. 1204 Community Pharmacy Fairness Act\nH.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 promoting Innovation and Access to Life Saving Medications Act\nH.R. 1549 Pathway for Biosimilars Act\n\nHealth Care Reform, Follow-on Biologics, Pharmaceutical Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Health IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 48245, "prefix": "mr", "prefix_display": "MR.", "first_name": "JERRY", "nickname": null, "middle_name": null, "last_name": "STEFFL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "S. 1697 Affordable Health Choices Act\nS. 1796 America's Health Choices Act\nH.R. 3200 America's Affordable Health Choices Act\nRegulatory provisions related to Medicare Part D. Provisions included in health reform proposals that would impact Part D, such as formulary requirements, anti-kickback statutes for generic drug copay waivers, Medicaid rebate changes, direct negotiation.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 48245, "prefix": "mr", "prefix_display": "MR.", "first_name": "JERRY", "nickname": null, "middle_name": null, "last_name": "STEFFL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "INS", "general_issue_code_display": "Insurance", "description": "S. 1697 Affordable Health Choices Act\nS. 1796 America's Health Choices Act\nH.R. 1204 Community Pharmacy Fairness Act\nH.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 promoting Innovation and Access to Life Saving Medications Act\nH.R. 1549 Pathway for Biosimilars Act\n\nHealth Care Reform, Follow-on Biologics, Pharmaceutical Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Health IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 48245, "prefix": "mr", "prefix_display": "MR.", "first_name": "JERRY", "nickname": null, "middle_name": null, "last_name": "STEFFL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "S. 1697 Affordable Health Choices Act\nS. 1796 America's Health Choices Act\nH.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 promoting Innovation and Access to Life Saving Medications Act\nH.R. 1549 Pathway for Biosimilars Act\n\nProvisions related to settlement payments between manufacturers to delay introduction of generic pharmaceutical products\n\nBenefit design and coverage of pharmaceutical benefits in health and PBM disclosure in health reform proposals\n\nHealth Care Reform, Follow-on Biologics, Pharmaceutical Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Health IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 48245, "prefix": "mr", "prefix_display": "MR.", "first_name": "JERRY", "nickname": null, "middle_name": null, "last_name": "STEFFL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | MN | US | MN | MN | US | US | 0 | 0 | 18000.0 |